Location History:
- Thousand Oaks, CA (US) (2015)
- Sherman Oaks, CA (US) (2021)
Company Filing History:
2 out of 1,975 
1 out of 3,923 
Years Active: 2015-2021
Title: Pedro J Beltran: Innovator in Cancer Treatment
Introduction
Pedro J Beltran is a notable inventor based in Sherman Oaks, CA (US). He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of 2 patents, Beltran's work focuses on methods and compositions that target tumor diseases.
Latest Patents
Beltran's latest patents include groundbreaking inventions aimed at treating tumor diseases. One patent details methods for treating tumors in human subjects by inhibiting IGF-1 receptor signaling. This invention provides methods for determining a tumor's likelihood of responding to treatment, along with compositions for practicing these methods. It includes fully human, humanized, or chimeric anti-IGF-1R antibodies that bind to human IGF-1R, as well as nucleic acids encoding these antibodies and methods for their use in treating IGF-1R-related disorders.
Another significant patent involves a pharmaceutical combination for cancer treatment. This invention relates to a combination of a MEK inhibitor and an IGF1R inhibitor antibody, along with methods for administering this combination to subjects in need. The innovative approach aims to enhance the effectiveness of cancer therapies.
Career Highlights
Throughout his career, Pedro J Beltran has worked with prominent companies in the pharmaceutical industry, including Amgen Inc. and Novartis AG. His experience in these organizations has contributed to his expertise in developing innovative treatments for cancer.
Collaborations
Beltran has collaborated with notable professionals in his field, including Xizhong Huang and Malte Peters. These collaborations have further enriched his research and development efforts.
Conclusion
Pedro J Beltran is a distinguished inventor whose work in cancer treatment has the potential to make a significant impact on patient care. His innovative patents reflect a commitment to advancing medical science and improving therapeutic outcomes for individuals facing tumor diseases.